This HTML5 document contains 150 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
wdthttp://www.wikidata.org/prop/direct/
wdtnhttp://www.wikidata.org/prop/direct-normalized/
schemahttp://schema.org/
rdfshttp://www.w3.org/2000/01/rdf-schema#
skoshttp://www.w3.org/2004/02/skos/core#
n10http://dx.doi.org/10.3324/
wikibasehttp://wikiba.se/ontology#
phttp://www.wikidata.org/prop/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n11http://rdf.ncbi.nlm.nih.gov/pubchem/reference/
xsdhhttp://www.w3.org/2001/XMLSchema#
wdshttp://www.wikidata.org/entity/statement/
wdhttp://www.wikidata.org/entity/

Statements

Subject Item
wd:Q37216472
rdf:type
wikibase:Item
schema:description
videnskabelig artikel наукова стаття, опублікована у квітні 2016 vědecký článek artigo científico article científic artículu científicu espublizáu en 2016 scientific article published on 14 April 2016 bilimsel makale vetenskaplig artikel wissenschaftlicher Artikel مقالة علمية نشرت في 14 أبريل 2016 vedecký článok wetenschappelijk artikel научни чланак articolo scientifico article scientifique
p:P577
wds:Q37216472-6E5AA2EC-4DC3-4CC1-A83F-76071CD4AC9F
wdt:P577
2016-04-14T00:00:00Z
p:P2860
wds:Q37216472-56515EA4-3F30-4DBE-AFAD-65359F56C5B0 wds:Q37216472-5B0A4029-DCFF-4702-BAE2-F4EC00A049DA wds:Q37216472-4CB22745-463D-4A16-B204-93669C4299AB wds:Q37216472-512873AD-4706-41DC-8121-A63A5E701A66 wds:Q37216472-6F2A8328-28B3-4C57-97A2-C75827D89814 wds:Q37216472-62970FAE-7EB7-4BBE-B73F-A5EC0A9AB5A0 wds:Q37216472-66D02206-EDA5-444F-B0A6-89C5A0DA385E wds:Q37216472-6CFE6EFC-2BF9-4F1D-A035-EB24E928DEF3 wds:Q37216472-174192F1-C9AC-47B8-A322-6CC424B74F79 wds:Q37216472-21E0523E-2812-406A-BEFD-F685EE976F42 wds:Q37216472-25F2287C-9135-41FA-874E-8CBB5FCA6B00 wds:Q37216472-19764844-0AB5-4BE9-AC48-500297031E8E wds:Q37216472-1C494C7A-8D7D-4AF1-B2AA-B2BAE873F2C8 wds:Q37216472-E50E8B68-DBD8-494A-8203-0ABA32B17E08 wds:Q37216472-D26B3B18-2C61-470C-816B-E2E0A0D8F8EB wds:Q37216472-DA63E614-6180-455B-9A3D-C37ACD317F6A wds:Q37216472-F65BFA18-C45A-49C2-9C6E-3FE7CD7F5B1D wds:Q37216472-FB0624B8-0E5C-49E4-A5D2-50D733D29C93 wds:Q37216472-EEFD4E6F-0016-48BF-AC23-2B46971BA3D3 wds:Q37216472-EFA52679-A57D-421A-B683-F3648497B9AB wds:Q37216472-F2EE6CF8-9CCA-4989-8DAA-BA3726A23FEE wds:Q37216472-9DEF74D8-626A-4914-831F-F9CCE209470B wds:Q37216472-A0428382-7B33-42ED-8894-8141AAE13E56 wds:Q37216472-87445883-3B91-4F43-9449-DAA6E78D41B8 wds:Q37216472-A2646330-2BB0-4EA7-B002-A16B4BC28F32 wds:Q37216472-A38B7028-36FB-4A1B-AC2E-EFFAD3B6D69D wds:Q37216472-B28547C0-9C20-4B0C-AD7E-8116EB97EB2A
wdt:P2860
wd:Q33410172 wd:Q83292538 wd:Q43472495 wd:Q36199188 wd:Q36301287 wd:Q43019139 wd:Q52469315 wd:Q24605861 wd:Q37983540 wd:Q53811677 wd:Q44738504 wd:Q35045634 wd:Q46936772 wd:Q33942495 wd:Q38201165 wd:Q29615603 wd:Q34008578 wd:Q68697517 wd:Q80011690 wd:Q68881186 wd:Q54480001 wd:Q73009081 wd:Q36478461 wd:Q37801221 wd:Q34038959 wd:Q33864162 wd:Q57904810
p:P2093
wds:Q37216472-CBE83D79-790A-414F-95E8-29919419CE92 wds:Q37216472-E8AF0CC7-BF73-469B-9E54-EB22BA8C1E28 wds:Q37216472-EA380BBC-8ACB-406B-A303-927A41A40E14 wds:Q37216472-07D27BAB-A700-4414-B8BF-D2B3CA2C46B2 wds:Q37216472-0E17C028-854D-4956-9524-6B102A5853EF wds:Q37216472-2130B6D7-CE31-44F8-9FF8-10BAE0CC25E7 wds:Q37216472-34A41EBA-34CD-43C3-96E3-2BDA809E9B02
wdt:P2093
Xin Yu Kevin W Song Christian Jacques Joaquin Martinez-Lopez Christine Chen Mohamed H Zaki Valentina Ivanova
rdfs:label
Analysis of renal impairment in MM-003, a phase III study of pomalidomide + low - dose dexamethasone versus high - dose dexamethasone in refractory or relapsed and refractory multiple myeloma Analysis of renal impairment in MM-003, a phase III study of pomalidomide + low - dose dexamethasone versus high - dose dexamethasone in refractory or relapsed and refractory multiple myeloma Analysis of renal impairment in MM-003, a phase III study of pomalidomide + low - dose dexamethasone versus high - dose dexamethasone in refractory or relapsed and refractory multiple myeloma.
skos:prefLabel
Analysis of renal impairment in MM-003, a phase III study of pomalidomide + low - dose dexamethasone versus high - dose dexamethasone in refractory or relapsed and refractory multiple myeloma Analysis of renal impairment in MM-003, a phase III study of pomalidomide + low - dose dexamethasone versus high - dose dexamethasone in refractory or relapsed and refractory multiple myeloma Analysis of renal impairment in MM-003, a phase III study of pomalidomide + low - dose dexamethasone versus high - dose dexamethasone in refractory or relapsed and refractory multiple myeloma.
schema:name
Analysis of renal impairment in MM-003, a phase III study of pomalidomide + low - dose dexamethasone versus high - dose dexamethasone in refractory or relapsed and refractory multiple myeloma Analysis of renal impairment in MM-003, a phase III study of pomalidomide + low - dose dexamethasone versus high - dose dexamethasone in refractory or relapsed and refractory multiple myeloma Analysis of renal impairment in MM-003, a phase III study of pomalidomide + low - dose dexamethasone versus high - dose dexamethasone in refractory or relapsed and refractory multiple myeloma.
p:P50
wds:Q37216472-1B488FC3-CD00-48DA-AB4A-7CB78E995C83 wds:Q37216472-39CB486A-6C57-47D4-860F-F54CA7CF44EF wds:Q37216472-0C5D8BBD-FBD4-4C4B-BCF7-350E208233F2 wds:Q37216472-13DF7DF2-8B2E-4B52-A518-649D909F2B75 wds:Q37216472-68C17B18-C2F3-4D89-8339-D6B03289068E wds:Q37216472-777E90D0-1D23-4DD9-9F3A-699DED70FF53 wds:Q37216472-4460C6F6-2728-4BDC-9256-C61DCAA0ADEF wds:Q37216472-4D766987-CF65-4CE6-A65B-4862E62F4471 wds:Q37216472-53CE4B48-5B78-42F1-9A52-3A57E46690CC wds:Q37216472-BD6C1A9D-D6AA-4BD5-97BE-5DA097FDF67E wds:Q37216472-81590EB9-E0AF-44EE-9328-5D6568409329 wds:Q37216472-9484909F-0A2D-453E-B698-2929C234B616 wds:Q37216472-9D22BCC8-2A19-4D5A-997A-1ED42E318DAE wds:Q37216472-9E6F7E76-0A62-4F30-AA78-E6234C3E424D wds:Q37216472-9F73DD98-38D7-4C6E-A390-5C3DB3A858E2 wds:Q37216472-ED2762AE-7EAB-43F3-8C0D-DD58E6EE948B
wdt:P50
wd:Q66419394 wd:Q87734443 wd:Q5930658 wd:Q96188536 wd:Q89982374 wd:Q97590668 wd:Q23061917 wd:Q114442085 wd:Q96475433 wd:Q89444137 wd:Q114442086 wd:Q92116116 wd:Q57233657 wd:Q47344831 wd:Q87664147 wd:Q26338766
p:P1476
wds:Q37216472-5DB728DB-A5FC-42F9-A922-EBD7FE5DC7F4
wdt:P1476
Analysis of renal impairment in MM-003, a phase III study of pomalidomide + low - dose dexamethasone versus high - dose dexamethasone in refractory or relapsed and refractory multiple myeloma
p:P304
wds:Q37216472-F333398A-47B9-49C3-B965-FD818F493CDE
wdt:P304
872-878
p:P31
wds:Q37216472-DDE4186E-8C37-49BC-9EB5-04C00746CB3D
wdt:P31
wd:Q13442814
p:P921
wds:Q37216472-7562472C-906E-4CD4-94EA-372DEF8D0D58
wdt:P921
wd:Q422252
p:P698
wds:Q37216472-0A0BC108-A674-4646-8F9B-0AAD86DFD228
wdtn:P698
n11:27081177
wdt:P698
27081177
p:P1433
wds:Q37216472-AAF00AC7-01AF-4BFB-9FAE-36AF9471022D
wdt:P1433
wd:Q5638209
p:P433
wds:Q37216472-BFF9EE39-C5A8-4DB4-B0E2-A58E5B276C19
p:P478
wds:Q37216472-CCA3DC83-4638-4A4B-8980-DAB545F76E7A
wdt:P433
7
wdt:P478
101
p:P356
wds:Q37216472-BCAFD988-AD60-4E2F-949A-3FFB80CB6C19
wdtn:P356
n10:HAEMATOL.2015.137083
wdt:P356
10.3324/HAEMATOL.2015.137083
p:P932
wds:Q37216472-E1888429-24FA-4F31-B581-68667BD98B72
wdt:P932
5004467